TY - JOUR
T1 - [3H]‐GUANFACINE
T2 - A RADIOLIGAND THAT SELECTIVELY LABELS HIGH AFFINITY α2‐ADRENOCEPTOR SITES IN HOMOGENATES OF RAT BRAIN
AU - JARROTT, BEVYN
AU - LOUIS, WILLIAM J.
AU - SUMMERS, ROGER J.
PY - 1982/1/1
Y1 - 1982/1/1
N2 - [3H]‐guanfacine (N‐amidino‐2‐(2,6‐dichloro 3[3H] phenyl) acetamide hydrochloride; 24.2 Ci/mmol) has been used as a radioligand in homogenates of rat cerebral cortex. Specific binding of [3H]‐guanfacine was linear with respect to tissue concentration (2.5–15 mg/ml), saturable and not markedly affected in the pH range 6.5–8.0. Analysis of the saturation of [3H]‐guanfacine binding using an iterative least squares fitting procedure gave best fits to a single site model. [3H]‐guanfacine binding was of high affinity (Kd 1.71 ± 0.24 nm; n = 8) to a population of non interacting sites (nH 0.99 ± 0.02; n = 8) with a density of 118.2 ± 8.4 fmol/mg protein (n = 8). Highest levels of binding were achieved in cerebral cortex followed by thalamus > hypothalamus > medulla/pons > spinal cord > striatum > cerebellum. Binding was stereoselective with regard to the (—)‐isomer of noradrenaline and the order of potency for displacement of [3H]‐guanfacine by agonists was naphazoline > clonidine > (—)‐adrenaline > (—)‐α methylnoradrenaline > (—)‐noradrenaline > (±)‐α‐methylnoradrenaline > (+)‐noradrenaline > methoxamine > (+)‐adrenaline > phenylephrine and by antagonists was phentolamine > dihydroergocryptine > piperoxane > yohimbine > prazosin > labetalol > indoramin suggested binding to α2‐adrenoceptors. The monovalent cations Na+ and K+ and also guanosine 5′‐triphosphate (GTP) produced concentration‐dependent inhibition whereas the divalent cations Ca2+, Mg2+, and Mn2+ first enhanced, then inhibited [3H]‐guanfacine binding. Na+ (150 mm) or GTP (100 μm) produced marked reductions and Mn2+ (5 mm) marked increases in the number of receptor sites labelled by [3H]‐guanfacine. It is concluded that [3H]‐guanfacine preferentially labels a high affinity state of the α2‐adrenoceptor in homogenates of rat cerebral cortex. 1982 British Pharmacological Society
AB - [3H]‐guanfacine (N‐amidino‐2‐(2,6‐dichloro 3[3H] phenyl) acetamide hydrochloride; 24.2 Ci/mmol) has been used as a radioligand in homogenates of rat cerebral cortex. Specific binding of [3H]‐guanfacine was linear with respect to tissue concentration (2.5–15 mg/ml), saturable and not markedly affected in the pH range 6.5–8.0. Analysis of the saturation of [3H]‐guanfacine binding using an iterative least squares fitting procedure gave best fits to a single site model. [3H]‐guanfacine binding was of high affinity (Kd 1.71 ± 0.24 nm; n = 8) to a population of non interacting sites (nH 0.99 ± 0.02; n = 8) with a density of 118.2 ± 8.4 fmol/mg protein (n = 8). Highest levels of binding were achieved in cerebral cortex followed by thalamus > hypothalamus > medulla/pons > spinal cord > striatum > cerebellum. Binding was stereoselective with regard to the (—)‐isomer of noradrenaline and the order of potency for displacement of [3H]‐guanfacine by agonists was naphazoline > clonidine > (—)‐adrenaline > (—)‐α methylnoradrenaline > (—)‐noradrenaline > (±)‐α‐methylnoradrenaline > (+)‐noradrenaline > methoxamine > (+)‐adrenaline > phenylephrine and by antagonists was phentolamine > dihydroergocryptine > piperoxane > yohimbine > prazosin > labetalol > indoramin suggested binding to α2‐adrenoceptors. The monovalent cations Na+ and K+ and also guanosine 5′‐triphosphate (GTP) produced concentration‐dependent inhibition whereas the divalent cations Ca2+, Mg2+, and Mn2+ first enhanced, then inhibited [3H]‐guanfacine binding. Na+ (150 mm) or GTP (100 μm) produced marked reductions and Mn2+ (5 mm) marked increases in the number of receptor sites labelled by [3H]‐guanfacine. It is concluded that [3H]‐guanfacine preferentially labels a high affinity state of the α2‐adrenoceptor in homogenates of rat cerebral cortex. 1982 British Pharmacological Society
UR - https://www.scopus.com/pages/publications/0020002514
U2 - 10.1111/j.1476-5381.1982.tb08801.x
DO - 10.1111/j.1476-5381.1982.tb08801.x
M3 - Article
C2 - 6138110
AN - SCOPUS:0020002514
SN - 0007-1188
VL - 75
SP - 401
EP - 408
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 2
ER -